Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OncoMune, a provider of targeted cancer therapeutics, has appointed Christopher Dougherty, research professor at Florida Atlantic University, as its new chief scientific officer.
Subscribe to our email newsletter
Dr Dougherty has a doctorate in molecular and cellular pharmacology from the University of Miami Miller School of Medicine.
Boris Reznik, chairman of OncoMune, said: “Dr Dougherty has made many scientific advances in cellular biology as a member of the research faculty in the College of Biomedical Science at Florida Atlantic University. We are eager to add his talents and experience as we continue to develop cancer vaccines and RNA interference based therapeutics.”